ADC-RadCon 2027
World Forum on Antibody-Drug Conjugates, Targeted Radiopharmaceuticals & Theranostics. Convening oncology program directors, radiopharmaceutical chemists, and clinical PIs to resolve critical therapeutic barriers across linker stability, targeted alpha payloads, and GMP isotope supply chains.
Scientific Program Scope & Practice Framework
Accelerating the translational transition from novel linker synthesis and alpha emitters into verified hospital bedside theranostics.
Precision oncology is undergoing a fundamental paradigm shift through the convergence of antibody-drug conjugates (ADCs) and targeted radiopharmaceuticals. While novel cleavable linkers and high-potency payloads have validated clinical utility in refractory solid tumors, long-term survival rates remain challenged by systemic off-target toxicities, drug-to-antibody ratio (DAR) instability, and therapeutic resistance.
The World Forum on Antibody-Drug Conjugates, Targeted Radiopharmaceuticals & Theranostics (ADC-RadCon 2027) provides an international, high-rigor forum for hospital clinical oncologists, nuclear medicine physicians, radiopharmacy directors, and biotech developers. Convening across plenary podium lectures, proffered paper defenses, and bilateral matchmaking suites, participants evaluate next-generation alpha-emitting radionuclides, Topoisomerase I payloads, and macrocyclic chelation complexes.
Primary translational directives include standardizing Ga-68/Lu-177 theranostic dosimetry models, scaling Actinium-225 and Lead-212 production to eliminate trial shortages, and pioneering site-specific hydrophilic linkers that widen the clinical therapeutic window in treatment-resistant malignancies.
Academic & Clinical Governance
- Double-blind scientific abstract evaluation conducted under the Declaration of Helsinki research ethics charter.
- Rolling review protocol ensuring editorial determination within 10 business days of submission.
- Strict commercial firewall safeguarding podium presentations from uncurated vendor influence.
- Dedicated clinical question-and-answer floor critiques structured into every podium session.
Scientific Tracks & Subject Taxonomy
Proffered abstracts and podium sessions are categorized across five core scientific and clinical disciplines.
Novel Chemistries & Cleavable Linker Design
- Site-specific enzymatic and chemical conjugation platforms.
- Hydrophilicity modulators preventing premature systemic payload shedding.
- Plasma stability kinetics and lysosomal protease-cleavable architectures.
- Uniform DAR optimization and reduction of unreacted antibody fractions.
Next-Gen Warheads & Payload Modalities
- Topoisomerase I inhibitors overcoming microtubule-resistance pathways.
- Immune-stimulating antibody conjugates (ISACs) and STING agonists.
- Bispecific ADCs targeting heterogeneous solid tumor microenvironments.
- Targeted protein degradation payloads (DACs) and transcription blockers.
Targeted Alpha Therapies (TAT) & Radioligands
- Actinium-225 (225Ac), Lead-212 (212Pb), and Astatine-211 (211At) chelation.
- Macrocyclic chelator stability preventing toxic daughter recoil release.
- Peptide- and small molecule-based radioligand pharmacokinetic tuning.
- High-LET radiation mechanisms in inducing double-strand DNA breaks.
Clinical Theranostics & Dual-Action Imaging
- Gallium-68 diagnostic stratification paired with Lutetium-177 radiotherapy.
- Single-cell dosimetry and 3D voxel-based PET/SPECT biodistribution.
- Theranostic trial designs in mCRPC, neuroendocrine, and lung carcinomas.
- Overcoming renal and bone marrow critical organ dose constraints.
Isotope Supply Chain, GMP & Safety Toxicology
- Reactor vs. cyclotron and LINAC production pathways for 225Ac.
- Automated hot-cell radiochemistry and microfluidic synthesis modules.
- GMP grade analytical quality control for short-half-life radiopharmaceuticals.
- Preclinical toxicology models predicting off-target organ radiation toxicity.
Target Audience & Educational Objectives
Bridging synthetic bioorganic chemistry with nuclear medicine hospital practices and clinical oncology trials.
Intended Target Audience
This educational and scientific activity is structured for multi-disciplinary specialists:
- Medical Oncologists & Clinical Trial PIs: Evaluating active Phase I–III multicenter trials, safety endpoints, and combination regimens.
- Nuclear Medicine Physicians & Radiopharmacists: Managing hospital radiopharmacy suites, patient-specific dosimetry, and PET/SPECT theranostics.
- Bioconjugation Chemists & Radiochemists: Designing novel chelation cages, cleavable peptides, and cytotoxic warheads.
- Oncology Residents, Postdoctoral Fellows & Trainees: Presenting original bench-to-bedside research and networking with global department heads.
- Biopharma Heads of CMC & CDMO Partners: Engineering cGMP manufacturing, hot-cell containment, and automated radiochemical synthesis.
Educational Learning Objectives
Upon completion of the 14.5 contact-hour curriculum, participants will be equipped to:
- Analyze Conjugate Stability: Differentiate systemic pharmacokinetic behavior, bystander killing effects, and payload shedding among clinical ADCs.
- Optimize Radioligand Dosimetry: Calculate individual organ absorbed doses using voxel-based quantitative SPECT/CT to minimize renal and marrow toxicities.
- Formulate Alpha Therapy Protocols: Evaluate the biophysical advantages and isotope stability of 225Ac and 212Pb complexes in resistant solid tumors.
- Navigate Regulatory & Supply Frameworks: Implement cGMP compliance protocols for clinical trial supply, automated radiolabeling, and radioprotection standards.
Important Deadlines & Schedule
The review directorate reviews proffered abstracts on a rolling 10-business-day cycle. Please observe the formal dates below.
Colloquium Participation Tiers
All passes include full access to scientific tracks, lunch symposia, networking receptions, and verification for 14.5 Educational Contact Hours.
Clinical Delegate & Faculty (Non-Presenting Pass)
For hospital oncologists, radiopharmacists, and university faculty attending to evaluate cutting-edge clinical data and claim 14.5 contact hours without abstract submission.
Accepted Presenting Author (Oral Defense or Poster)
Subsidized author pass. Includes an assigned 15-minute plenary defense or hall poster display board, inclusion in the proceedings compendium, and all delegate privileges.
Postdoc / Fellow / Trainee (Verification Letter Required)
Subsidized institutional rate for medical residents, radiochemistry fellows, and graduate students. Verification letter from department chair required upon badge collection.
Virtual Technical Pass (Remote E-Poster & Webcast)
For overseas clinical investigators presenting asynchronously. Includes digital e-poster hosting, live plenary webcast access, and an electronic Certificate of Participation.
Need institutional invoicing, hospital wire transfers, or official letters of invitation?
Contact Central Electronic Desk for Institutional Invoicing & Group Inquiries →Isotope Supply, Conjugation CDMOs & Matchmaking Suites
Connecting radiochemical isotope producers, bioconjugation CDMOs, and analytical platforms directly with hospital radiopharmacy directors and biotech trial sponsors.
Lead Category Partner
Sovereign plenary dominance. Includes the exclusive 25-minute opening keynote address, 10 guaranteed 1-on-1 private buyer briefings, and category exclusivity across the colloquium.
Strategic Briefing Partner
Spotlight technical session. Features a dedicated 15-minute presentation in Track 01, 03, or 05, paired with 6 guaranteed bilateral briefings with clinical PIs and heads of CMC.
Turnkey Matchmaking Host
Turnkey executive foyer briefing station. Direct access to 4 pre-qualified buyer meetings arranged by the Secretariat with hospital and biotech procurement executives.